Neumora Therapeutics (NMRA) Capital Expenditures (2022 - 2023)
Neumora Therapeutics' (NMRA) quarterly Capital Expenditures came in at $44000.0 in Q4 2023, down 90.93% year-on-year from $485000.0 in Q4 2022, and up 18.92% quarter-over-quarter from $37000.0 in Q3 2023.
Neumora Therapeutics (NMRA) Capital Expenditures (2022 - 2023) Analysis & Trends
Neumora Therapeutics' Capital Expenditures history runs 2 years deep, the most recent figure standing at $44000.0 for Q4 2023.
- On a quarterly basis, Capital Expenditures fell 90.93% year-over-year to $44000.0 in Q4 2023; TTM through Dec 2023 was $117000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $117000.0, down 76.83% from the prior year.
- Capital Expenditures climbed to $44000.0 in Q4 2023 per NMRA's latest filing, from $37000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $485000.0 in Q4 2022 and bottomed at $36000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Neumora Therapeutics | 280.60 Mn | 280.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 44,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | 37,000.00 |
| Sep 30, 2023 | 37,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Dec 31, 2022 | 485,000.00 |
| Dec 31, 2022 | 485,000.00 |